Publications

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (B)

By: Sandra J. Sucher and Stacy McManus

When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details

Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Biotechnology Industry; Biotechnology Industry

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (A)

By: Sandra J. Sucher and Stacy McManus

Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details

Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Biotechnology Industry

2007
Chapter

Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business

By: Rohit Deshpandé and Zoe Chance

Keywords: Health Disorders; Poverty; Product Marketing; Customers; Biotechnology Industry; Biotechnology Industry

2004
Chapter

Genzyme's Gaucher Initiative: Global Risk and Responsibility

By: Christopher A. Bartlett and Andrew N. McLean

Keywords: Health Disorders; Corporate Social Responsibility and Impact; Globalization; Risk and Uncertainty; Biotechnology Industry; Biotechnology Industry

Web

Collection Highlights | Baker Library

in the financing of the transcontinental railroad and development of the electrical industry. Henri A. Termeer Papers Document the career of an entrepreneur and biotechnology executive known for leading Genzyme Corporation from 1983 to... View Details

01 Jun 2000
News

Managing the Map

We are at the dawn of a new epoch in the world of science, one that will cast strong light on a unique corner of the biotechnology field known as genomics. The designation refers to the study of genes, those chemical building blocks of... View Details

Keywords: Peter K. Jacobs

05 Dec 2013
Op-Ed

Encourage Breakthrough Health Care by Competing on Products Rather Than Patents

Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics maker Myriad sought "the... View Details

Keywords: by Richard G. Hamermesh; Biotechnology; Biotechnology

26 Jul 2024
Research & Ideas

Why Great Ideas Get Stuck in Universities

Entrepreneurs must overcome many barriers to get discoveries to market, but academic researchers face an additional one they might not realize: themselves. Academics tend to develop a myopic focus on the unique expertise they spend their lives developing, but that... View Details

Keywords: by Ben Rand; Biotechnology; Biotechnology

May 1999
Teaching Note

Elliot Lebowitz TN

By: Paul A. Gompers

Teaching Note for (9-297-094). View Details

Keywords: Biotechnology Industry

January 1998 (Revised September 2001)
Case

Genset: 1989

By: Paul A. Gompers and Amy Burroughs

Discusses the start-up strategy at Genset, a French biotech firm. Pascal Brandys, a venture capitalist, and Marc Vasseur, a leading French scientist, must decide how to proceed. Future real options are central to the strategy. View Details

Keywords: Strategy; Venture Capital; Business Startups; Biotechnology Industry; France

June 1997 (Revised September 1997)
Case

Genset Initial Public Offering (B)

By: Paul A. Gompers and Jeffrey M. Anapolsky

Supplements the (A) case. View Details

Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States

March 2018 (Revised July 2018)
Case

Greenlight Biosciences: In Search of Impact Investment

By: Michael Chu, Annelena Lobb and Joni Coughlin

Greenlight Biosciences, a biotech company, is in search of impact investment for its next round of financing. View Details

Keywords: Impact Investment; Investment; Environmental Sustainability; Financing and Loans; Biotechnology Industry

November 2016
Case

Anthony Starks at InSiL Therapeutics (A)

By: Gary Pisano and Vicki Sato

When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a few months in, Wayne and Starks begin to clash over crucial forward-looking decisions about the... View Details

Keywords: Biotech; Silicon; Managing Innovation; Management Challenges; Managing People; Managing Organization; R＆D; R＆D Project Management; Platform; Venture Capital; Drug Discovery; management; Biotechnology Industry; California

January 2012 (Revised August 2012)
Case

Dirigo International

By: Christopher M. Gordon and Chad M. Carr

Dirigo International is proposing a major expansion of their life sciences research and manufacturing facilities in the heart of a major city and middle to lower income residential neighborhood. The company and city government are seeking a development solution in the... View Details

Keywords: Production; Property; Expansion; Governing Rules, Regulations, and Reforms; Business and Government Relations; Research and Development; Outcome or Result; Biotechnology Industry

August 2010 (Revised August 2012)
Supplement

Generation Health: A Pioneer in Genetics Benefit Management (B)

By: Robert F. Higgins

Keywords: Health; Research and Development; Biotechnology Industry

January 2010 (Revised August 2011)
Case

Ganeden Biotech, Inc.

By: Robert C. Pozen, Dale Alan Winger and Matthew Kenneth Ahlers

The CEO of Ganeden Biotech, a small firm with several viable probiotic products but limited resources, must decide what markets to invest in and what intellectual property strategies will best serve its immediate and longer-term business interests. View Details

Keywords: Entrepreneurship; Investment; Intellectual Property; Market Entry and Exit; Business Strategy; Biotechnology Industry

November 2009 (Revised March 2010)
Case

Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story

By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon

In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details

Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States